Schering anesthesia drug appears safe, says FDA panel
SILVER SPRING, Maryland (Reuters) - A Schering-Plough Corp drug aimed at reversing the effects of anesthesia can be safely used in the targeted patient population, U.S. regulatory advisers said on Tuesday.
The Food and Drug Administration expert panel is considering the risks and benefits of the drug, to be called Bridion, and known generically as sugammadex. The FDA typically takes the advice of its advisory panels.
The drug aims to reverse the muscular blocking effects of certain muscle relaxants and help patients recover more quickly from anesthesia after medical procedures.
(Reporting by Kim Dixon; editing by Jeffrey Benkoe)